Mitochondrial medicine company NeuroVive Pharmaceutical AB (STO:NVP) reported on Tuesday loss before tax of SEK25,481,000, or SEK0.40 per diluted share, for the second quarter of 2018, from, April 2018 to June 2018.
This was a decline over loss before tax of SEK22,256,000, or SEK0,45 per diluted share, in q2 2017.
Net revenues for the quarter were nil, the same as in Q2 2017.
Other operating income for the quarter was SEK1,278,000, as compared with SEK88,000 in Q2 2017.
NeuroVive Pharmaceutical has one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases.
(EUR1.00=SEK10.53)
Perrigo announces quarterly dividend increase
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging